Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Unknown 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 209Sarcoma 33Tumor-Agnostic 21CNS 10Thoracic 9Genitourinary 8Other solid neoplasm 6Gynecologic 6Dermatologic 5Other hematologic neoplasm 4Head & Neck 4Breast 3Plasma cell 2Myeloid 2Lymphoid 2Endocrine 2NET 1Classical hematology 1

Conditions

Melanoma 5Uterine Cervical Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Noonan Syndrome 6 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
regorafenib × Dermatologic × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown
48 enrolled
Dermatologic

Melanoma

NCT02307500 2022-09-10

RESOUND

Istituto Clinico Humanitas

Phase 2 Completed
82 enrolled
DermatologicGastrointestinalGynecologicSarcomaThoracic

Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Thymoma

NCT02501551 2021-04-05

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Yonsei University

Phase 2 Unknown
36 enrolled
Dermatologic

Melanoma

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡